RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.

Rallybio (RLYB) announced that it has entered into a definitive agreement to sell its interest in REV102, an ENPP1 inhibitor ...

Detailed price information for Rallybio Corporaton (RLYB-Q) from The Globe and Mail including charting and trades.